No Data
No Data
Grace Therapeutics On Track For NDA Submission Of GTx-104 For Aneurysmal Subarachnoid Hemorrhage
Grace Therapeutics GAAP EPS of -$0.36 Misses by $0.04
Grace Therapeutics Reports Positive Phase 3 STRIVE-ON Trial Results for GTx-104 and Secures $30 Million in Financing; NDA Submission Expected by Mid-2025
Grace Therapeutics | 8-K: Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update
Grace Therapeutics 3Q Loss/Shr 36c >GRCE
Press Release: Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update